Physician profile
Daniel C Hemple
NPI 1326444910
$1,725.89
in general payments reported to CMS, 2019-2025
25 companies · $16.65 in 2025
The $16.65 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $347 · 2023: $573 · 2024: $789 · 2025: $16.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,378.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $371.34 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $204.04 | 2023-2024 | |
| Lilly USA, LLC | $137.98 | 2024 | Mounjaro, Zepbound |
| Pfizer INC. | $117.71 | 2022-2025 | |
| Daiichi Sankyo INC. | $98.86 | 2022-2023 | Injectafer |
| Harmony Biosciences LLC | $88.34 | 2023-2024 | Wakix |
| Bayer Healthcare Pharmaceuticals INC. | $79.58 | 2022-2024 | |
| Glaxosmithkline, LLC. | $71.53 | 2023-2024 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $67.25 | 2022-2023 | Belsomra |
| Astellas Pharma US INC | $67.17 | 2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $66.66 | 2023-2024 | Farxiga, Breztri |
| Dynavax Technologies Corporation | $41.97 | 2022-2023 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $41.47 | 2024 | Voquezna |
| Exact Sciences Corporation | $36.22 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $34.49 | 2023-2024 | Repatha, Otezla |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $25.84 | 2024 | NP Thyroid 60 |
| Alexion Pharmaceuticals, INC. | $24.98 | 2022 | |
| Boston Scientific Corporation | $24.61 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.60 | 2024 | Trintellix |
| Inspire Medical Systems, INC. | $22.59 | 2023 | Inspire |
| Idorsia Pharmaceuticals US INC | $17.68 | 2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $16.76 | 2023 | Rexulti, Abilify Maintena |
| Tolmar, INC. | $16.66 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $14.76 | 2023 | |
| Lundbeck LLC | $13.80 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hemple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.